Results 41 to 50 of about 17,743 (275)

Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines [PDF]

open access: yes, 2015
Malignant mesothelioma is rare and difficult to diagnose. Its identification depends upon pathological investigation (cyto-histological assessment and immunohistochemistry) supported by clinical and radiological evidence.
Ascoli, Valeria
core   +2 more sources

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort [version 1; referees: 1 approved, 2 approved with reservations]

open access: yesF1000Research, 2018
Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US.  Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for ...
Waqas Amin   +4 more
doaj   +1 more source

Quantitative Assessment of Asbestos Fibers in Normal and Pathological Peritoneal Tissue—A Scoping Review

open access: yesLife, 2022
Peritoneal tissue is the second most affected site by malignant mesothelioma linked to asbestos exposure. This scoping review aims to summarize the findings of the studies in which asbestos fibers in the peritoneum were quantified by electron microscopy,
Yohama Caraballo-Arias   +8 more
doaj   +1 more source

Malignant peritoneal mesothelioma as a rare cause of ascites: a case report

open access: yesJournal of Medical Case Reports, 2008
Introduction Peritoneal mesothelioma is a rare tumor with diagnostic and therapeutic problems. The peritoneum is the second most common site for development of mesothelioma, which in 30–45% of cases is associated with a synchronous pleural mesothelioma ...
Ahmed Iftikhar   +3 more
doaj   +1 more source

Survival prediction in mesothelioma using a scalable lasso regression model: instructions for use and initial performance using clinical predictors [PDF]

open access: yes, 2018
Introduction: Accurate prognostication is difficult in malignant pleural mesothelioma (MPM). We developed a set of robust computational models to quantify the prognostic value of routinely available clinical data, which form the basis of published MPM ...
Blyth, Kevin G.   +5 more
core   +1 more source

Peritoneal malignant mesothelioma with epithelioid type, demonstrating high serum and ascitic KL-6 levels: immunohistochemical analyses

open access: yesRare Tumors, 2015
We report a case of KL-6 producing peritoneal malignant mesothelioma. A 56-year-old woman was referred to our hospital on November 2005 with severe abdominal distention.
Saifun Nahar   +11 more
doaj   +1 more source

Advances in the design and development of oncolytic measles viruses. [PDF]

open access: yes, 2015
A successful oncolytic virus is one that selectively propagates and destroys cancerous tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles virus (MV) is one such virus that exhibits this characteristic and thus has
Hutzen, Brian   +2 more
core   +1 more source

Malignant peritoneal mesothelioma

open access: yesWorld Journal of Gastrointestinal Surgery, 2009
Malignant mesothelioma is a highly aggressive neoplasm. The incidence of malignant mesothelioma is increasing worldwide. Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas. Association of asbestos exposure with DMPM has been observed, especially in males.
Stine, Munkholm-Larsen   +2 more
openaire   +2 more sources

Peritoneal Mesothelioma: An Unusual Cause of High-Protein Ascites [PDF]

open access: yes, 2015
We present a case illustrating the workup and diagnosis of peritoneal sarcomatous mesothelioma as an unusual etiology of intestinal obstruction and high-protein ascites in an otherwise healthy man.
Kaspar, Matthew
core   +2 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy